Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S (NOVO B)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
01/10/2019 01/11/2019 01/14/2019 01/15/2019 01/16/2019 Date
314.55(c) 314.35(c) 303.3(c) 308.95(c) 307.5 Last
2 231 073 1 549 314 3 393 053 2 757 809 2 063 556 Volume
-0.80% -0.06% -3.52% +1.86% -0.47% Change
More quotes
Financials (DKK)
Sales 2018 112 B
EBIT 2018 47 756 M
Net income 2018 38 989 M
Finance 2018 15 538 M
Yield 2018 2,65%
Sales 2019 117 B
EBIT 2019 50 655 M
Net income 2019 40 037 M
Finance 2019 16 168 M
Yield 2019 2,78%
P/E ratio 2018 18,83
P/E ratio 2019 18,06
EV / Sales2018 5,06x
EV / Sales2019 4,80x
Capitalization 580 B
More Financials
Company
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The... 
Sector
Pharmaceuticals
Calendar
02/01Earnings Release
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
01/14NOVO NORDISK A/S : - Share repurchase programme
AQ
01/14CALLIDITAS THERAPEUTICS : appoints Frank Bringstrup as VP Regulatory Affairs
AQ
01/07NOVO NORDISK A/S : - Share repurchase programme
AQ
2018NOVO NORDISK A/S : Share repurchase programme
AQ
2018NOVO NORDISK A/S : Strongbridge Biopharma plc Announces Closing of Transaction w..
AQ
2018NOVO NORDISK A/S : Strongbridge Biopharma plc Announces Closing of Transaction w..
AQ
2018STRONGBRIDGE BIOPHARMA : Closes Deal With Novo Nordisk for Macrilen U.S., Canada..
DJ
2018NOVO NORDISK A/S : gets option to cardiovascular company Staten
AQ
2018NOVO NORDISK A/S : bags 430M Staten buyout option to boost cardiovascular diseas..
AQ
2018NOVO NORDISK A/S : Staten Biotechnology Strikes $488 Million Deal With Novo
DJ
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Stock Trading Strategies
NOVO NORDISK A/S - 2018
Attractive timing with a long term view to go long again
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
02:48aBAYER : Roundup Faces New Setback in France
DJ
01/15European nations weigh impact of Brexit on drug supplies
RE
01/15Drug companies greet 2019 with U.S. price hikes
RE
01/15French court cancels Monsanto weedkiller permit on safety grounds
RE
01/15BAYER : Faces New Setback for Roundup Weedkiller in France
DJ
More sector news : Pharmaceuticals - NEC
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 322  DKK
Spread / Average Target 6,3%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S3.71%88 621
JOHNSON & JOHNSON-0.60%344 044
PFIZER-2.93%245 746
NOVARTIS3.55%221 313
ROCHE HOLDING LTD.5.59%220 097
MERCK AND COMPANY-2.50%190 790